February 13, 2019 Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
Abilita Bio, Inc., announced today that it has entered into a multi-target research collaboration agreement with Amgen, Inc. (AMGN), a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s R&D efforts on challenging integral membrane protein targets.
September 1, 2018 Abilita Bio Awarded NIH Phase-I SBIR Grant to Discover Non-Opioid Pain Therapeutics
Abilita Bio, Inc., announced the award of a Phase I SBIR Grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to fund the discovery of novel biologic agents that target human voltage-gated sodium (NaV) channels for the non-opioid treatment of pain.
December 13, 2017 X-Chem and Abilita Bio Announce a Joint Research Collaboration
X-Chem, Inc. and Abilita Bio, Inc., both privately held biotechnology companies, announced today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCRs) and ion channel targets.
October 11, 2017 Abilita Bio Announces the Appointment of Charlie Rodi, PhD to the Executive Advisory Board
Abilita Bio, Inc. today announced the appointment of Dr. Charlie Rodi to the company’s Executive Advisory Board. For more information about Dr. Rodi please follow the link below.
January 30, 2017 Abilita Bio Signs a New Research Collaboration with a Global Pharmaceutical Company and 2016 Milestone Review
Abilita Bio, Inc. announced today a second research collaboration agreement with a major pharmaceutical partner, which will leverage Abilita Bio’s proprietary EMP™ membrane protein evolution platform to accelerate G protein-coupled receptor (GPCR) drug discovery and development.
September 20, 2016 Abilita Bio, Inc. Awarded NCI Phase-I SBIR Grant to Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer
Abilita Bio, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop therapeutic antibodies targeting G Protein-Coupled Receptors (GPCRs) involved in the metastasis of breast cancer, including prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 4 (EP4), and C-C chemokine receptor 7 (CCR7).
April 12, 2016 Abilita Bio Appoints Christopher B. Roth, PhD to Vice President, Innovation
Abilita Bio, Inc. announced today that Christopher B. Roth has been appointed to the role of Vice President, Innovation. In conjunction with this appointment, Dr. Roth will step down as a member of Abilita Bio’s Scientific Advisory Board, which he joined in 2015.
December 14, 2015 Primordial Genetics and Abilita Bio Establish Collaboration to Produce Stabilized G Protein-Coupled Receptors (GPCRs) in Bacteria
Abilita Bio Inc. and Primordial Genetics Inc., a biotechnology company that provides genetic solutions for improvement of production microbes, have signed a collaboration agreement for use of Primordial Genetics’ Function Generator™ genetic improvement technology to develop advanced strains of E. coli for expression of mammalian membrane proteins that have been optimized for structural and drug development efforts using Abilita’s proprietary Enabled Membrane Proteins (EMPs™) technology. To learn more about Primordial Genetics, please see www.primordialgenetics.com
Tracy Handel, PhD: Pharmacology
Professor of Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Pharmacology
Wei Liu, PhD: Crystallography
Assistant Professor, Arizona State University Department of Chemistry & Biochemistry and The Biodesign Institute, Applied Structural Discovery
